leadf
logo-loader
viewBioVaxys Technology Corp.
(
CSE:BIOVOTCQB:BVAXF
)

BioVaxys Technology says DTH response persists for at least one year after coronavirus exposure or vaccination

Study results showed that the DTH test can be used as a routine diagnostic method to monitor the T cell-mediated response to SARS-CoV-2

BioVaxys Technology Corp says DTH response persists for at least one year after coronavirus exposure or vaccination
ECI is one of the most highly-regarded international conferences in the field of basic and clinical immunology

BioVaxys Technology Corp said a further study in humans shows that the delayed type hypersensitivity (DTH) response, the basis for CoviDTH, its disposable diagnostic tool that screens for T-cell immune response to SARS-CoV-2, is highly durable and persists for at least one year after coronavirus (COVID-19) exposure or vaccine administration. 

Its Scientific Advisor for its CoviDTH program, Yvelise Barrios and Clinical Immunologist at Hospital Universitario de Canarias, Tenerife, Spain, presented the new clinical study entitled ‘Long term follow-up of in vivo cellular immune response to SARS-CoV-2 using delayed-type hypersensitivity cutaneous test’ at the 6th European Congress of Immunology held September 1-4, 2021. 

ECI is one of the most highly-regarded international conferences in the field of basic and clinical immunology. 

READ: BioVaxys says trial affirms CoviDTH approach to screen for T cell-mediated immune response to SARS-CoV-2 is effective in humans

Dr Barrios is a leading expert in the clinical use of DTH, the mechanism behind CoviDTH.

Her collaborators were Inmaculada Sanchez Machín and Victor Matheu, Allergology Department and Grupo de Expertos Inmunodeficiencias, Hospital Universitario de Canarias, Tenerife. 

Their study shows that the DTH response, which is the basis for CoviDTH, in individuals who had recovered from COVID-19 is highly durable, persisting for at least one year after viral exposure in these preliminary data. They conclude that the DTH test can be used as a routine diagnostic method to monitor the T cell-mediated response to SARS-CoV-2.

Study results

Two recovered patients were tested for DTH at six and 12 months after infection. The DTH responses were considered very “large responses”, compared, for example, to the DTH responses of people with a history of tuberculosis.

These results pointed out that natural, acquired immunity in these two patients is still very clearly present after one year of follow-up and that the DTH is a very simple and easy to interpret test to answer questions about durability of cellular immune responses in COVID-19.

In June 2021, Dr Barrios and her colleagues had previous human studies of DTH published in the medical research journals Vaccines and Clinical Immunology, which validated the use of the CoviDTH approach of a DTH cutaneous test as a feasible and safe in vivo method to assess cellular immune responses in both natural and vaccinated SARS-CoV-2 exposed individuals.

There is significant evidence that an antibody-mediated and T cell-mediated immune response is required for protection against SARS-CoV-2 and that T cell-mediated immunity is a more reliable correlate of vaccine protection than antibody titers in seniors, strongly supporting the need for a determination of T cell response in COVID-19 vaccine design and population screening.

Preparing IND

Kenneth Kovan, President and Chief Operating Officer of BioVaxys, said: "These human studies conducted by Dr. Barrios give us significant confidence in CoviDTH, especially as we now are preparing our IND for the planned US combined Phase I/II study."

For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

Quick facts: BioVaxys Technology Corp.

Follow
CSE:BIOV

Price: 0.49 CAD

Market Cap: $39.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

3 days, 4 hours ago

3 min read